← Human Trials & Peer-Reviewed Studies
Monthly High-Dose Vitamin D Supplementation and Cancer Risk: A Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial.
Plain-language guide to PMID 30027269 (2018): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 47,905 adults.
Key Facts
- PMID
- 30027269
- Journal
- JAMA oncology
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Scragg R et al. (8 authors)
- DOI
- 10.1001/jamaoncol.2018.2178
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
Previous randomized clinical trials have reported inconsistent results on the effect of vitamin D supplementation on cancer incidence.
Who Took Part
The study group was 47,905 adults.
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.
Participants were adult community residents aged 50 to 84 years.
Of 47 905 adults invited from family practices and 163 from community groups, 5110 participants were randomized to receive vitamin D3 (n = 2558) or placebo (n = 2552).
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
Two participants withdrew consent, and all others (n = 5108) were included in the primary analysis.
Data analysis was by intention to treat.
What Was Measured
Topics PubMed links to this paper include Dietary Supplements, Incidence, Neoplasms and Vitamin D.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 47,905 adults.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (JAMA oncology), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.